Composition comprising polyphenol

• US 20090012183A1
• Filed: 07/02/2008
• Published: 01/08/2009
• Est. Priority Date: 07/05/2007
• Status: Abandoned Application

• Current Assignee: Conopco, Inc. (Unilever PLC)
• Original Assignee: Conopco, Inc. (Unilever PLC)
• Inventors: Draijer, Richard, De Mey, Jozef Gabriel Rita, Van Dorsten, Ferdinand Alexander
• Application Number:
  US12/217,275
• Publication Number:
  US 20090012183A1
• Time in Patent Office: Days
• US Class Current: 514/733
• CPC Class Codes: A23C 11/103 containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
• CPC Class Codes: A23C 9/1307 Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
• CPC Class Codes: A23C 9/152 containing additives fermented milk preparations containing additives A23C9/13
• CPC Class Codes: A23D 7/0056 Spread compositions
• CPC Class Codes: A23D 7/013 Spread compositions
• CPC Class Codes: A23L 11/65 Soy drinks
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/326 having effect on cardiovascular health
• CPC Class Codes: A23V 2250/2132 Other phenolic compounds, polyphenols
• CPC Class Codes: A61K 31/045 Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

A food product comprising from 0.05 to 1 wt % of trans-resveratrol can advantageously be used to control blood pressure. Preferred food products are spreads or drinks.

Claims

1. A food product comprising trans-resveratrol, wherein the level of trans-resveratrol is from 0.05 to 1.0 wt %.

2. A food product according to claim 1 being a drink.

3. A food product according to claim 1 being a spread.

4. A fat based spread comprising from 10-85 wt % of fat and 10-90 wt % of water, wherein the spread comprises 0.05 to 1.0 wt % of trans-resveratrol, more preferred 0.1 to 0.9 wt % of trans-resveratrol, most preferred 0.4 to 0.75 wt % of trans-resveratrol.

6. A fat based spread according to claim 4 comprising from 20-85 wt % of vegetable fat and optionally 0-5 wt %, for example from 0.1 to 2 wt % of animal fat or marine oil.

7. A fat based spread according to claim 4 comprising from 0.1 to 15 wt % p, more preferred from 0.3 to 8 wt % of phytosterols, phytostanols or derivatives thereof, preferably fatty acid ester derivatives thereof.

8. A spread according to claim 4, comprising from 0.05 to 5.0 wt % Potassium ions per kg.

5. A drink, especially a dairy based drink, wherein the drink comprises from 10 to 95 wt % of a dairy base such as cow milk, soy milk or yoghurt, especially preferable cow milk or yoghurt, and 0.05 to 1.0 wt % of trans-resveratrol, more preferred 0.1 to 0.9 wt % of trans-resveratrol, most preferred 0.4 to 0.75 wt % of trans-resveratrol.

11. A drink according to claim 5 comprising from 0.1 to 15 wt % p, more preferred from 0.3 to 8 wt % of phytosterols, phytostanols or derivatives thereof, preferably fatty acid ester derivatives thereof.

12. A drink according to claim 5, comprising from 0.05 to 5.0 wt % Potassium ions per kg.

9. Use of 0.05 to 1.0 wt % of trans-resveratrol in the preparation of a food product for use in decreasing or otherwise controlling blood pressure.

10. Use according to claim 9 wherein the decreasing of blood pressure is by vasorelaxation.